Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Approaches in Cancer Study

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer

  • Open or Close Nibash Budhathoki1, Ajay Dhakal2* and Mateusz Opyrchal2

    1Department of Medicine, Interfaith Medical Center, USA

    2Department of Medicine, Roswell Park Cancer Institute, USA

    *Corresponding author: Ajay Dhakal, Clinical Fellow, Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, Elm and Carlton Streets, 14263, Buffalo, New York, USA

Submission: August 09, 2017; Published: August 21, 2017

DOI: 10.31031/NACS.2017.01.000501

ISSN:2637-773X
Volume1 Issue1

Abstract

Keywords:Immune Checkpoint Inhibitors; Triple Negative Breast Cancer; Breast Cancer; PD1; PD-L1, Pembrolizumab; Nivolumab; Atezolizumab

Abbreviations: CTLA4: Cytotoxic T Lymphocyte Antigen 4; PD1: Programmed Death 1; BMS: Bristol Myers Squibb; TIL: Tumor Infiltrating Lymphocytes; TNBC: Triple Negative Breast Cancer; IHC: Immunohistochemistry; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PFS: Progression Free Survival; IC: Immune Cells; ORR: Overall Response Rate; pCR: Pathological Complete Response; HR: Hormone Receptor

Get access to the full text of this article


About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com